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Abstract
Aging is signiﬁcantly associated with the development of comorbid chronic conditions. These conditions indicate the use of multiple
medications, and are often warranted by clinical guidelines. The aim of the present study was to evaluate medication appropriateness
and frailty among Malaysian aged care home residents with chronic disease. The participants were 202 elderly (≥65 years)
individuals, a cross-sectional sample from 17 aged care homes. After ethics approval, each participant was interviewed to collect
data on sociodemographics, frailty status (Groningen Frailty Indicator [GFI]), medication appropriateness (Medication
Appropriateness Index (MAI), the 2015 Beers’ criteria (Potentially Inappropriate Medication [PIM]), and 2014 STOPP criteria
(Potentially Inappropriate Prescribing [PIP]). The ﬁndings show that 81% (n=164) and 42% (n=85) were taking medications for
cardiovascular and central nervous system-related conditions, respectively, and 34% were using medications for diabetes (n=69).
Each participant had a mean of 2.9±1.5 chronic diseases, with an average GFI score of 6.4±3.6. More than three-quarters of the
participants (76%) were frail and polypharmacy was a factor in nearly half (48%); 41% and 36%were prescribed at least one PIP and
PIM, respectively, whereas the average MAI score was 0.6 (range: 0–6). The number of medications used per participant correlated
signiﬁcantly and positively (0.21, P= .002) with GFI score. These ﬁndings reinforce the need for participants of aged care homes to
receive periodic medication review aimed at minimizing morbidity associated with inappropriate pharmacotherapy.
Abbreviations: CNS = central nervous system, CVD = cardiovascular diseases, DM = diabetes mellitus, GFI = Groningen Frailty
Index, MAI = medication appropriateness index, PIM = potentially inappropriate medication, PIP = potential inappropriate
prescription, STOPP = screening tool of older people’s potentially inappropriate prescriptions.
Keywords: aged care, chronic diseases, elderly, frailty, medication appropriateness[5]1. Introduction
Globally, the proportion of individuals over the age of 65
continues to growmore rapidly than other age groups.[1] In 2015,
Malaysia had approximately 2.4 million individuals (8.0%) aged
60 and above.[2] With increasing life expectancy and declining
birth rates, the proportion of older people aged 65 and above is
expected to make up over 15% of the total population by
2030.[2,3] As populations age, the importance of effective aged
care grows signiﬁcantly.[4] Although family remains the principal
care and support for elderly, there are older people who are livingEditor: Inyang Nora Osemene.
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1alone or in aged care facilities. The residents of aged care homes
often have multiple comorbidities including frailty.[6]
Aging is signiﬁcantly associated with the development of
comorbid chronic conditions. These conditions indicate the use of
multiple medications, and are often warranted by clinical
guidelines. Many of the attributes of aging such as vulnerability,
physical, and cognitive decline also apply to frailty.[7] Clinically,
frailty is a condition characterized by reduced physiological
reserve and increased vulnerability to adverse outcomes after
stressor events.[8] Such outcomes include hospitalization, insti-
tutionalization, falls, disability, and mortality.[8–11] The decline
in physiological reserve occurs with aging but, in frailty, this
decline is accelerated and the ability to maintain homoeostasis
starts to fail.[10,11] Frailty has been shown to be an important
limitation or constraint upon drug choice in the elderly.[12] The
frail elderly often have chronic conditions and progressive loss of
functional capability. Both reduce quality of life, especially in loss
of independence and dignity.[13,14] One study found 62% of
participants as frail and suffering from cardiovascular disease
(CVD).[15] Another common condition in the elderly is diabetes
mellitus (DM). This was supported by a statistics showing
approximately half of the patients with type 2 DM are over 65
years of age.[16,17] Diabetes is also associated with cognitive
decline and physical disability that are linked to the development
and worsening of frailty syndrome.[12]
Polypharmacy has been an ongoing concern among older
patients in terms of the number of prescribed medications and the
[18]
Hasan et al. Medicine (2017) 96:35 Medicinecomplexity of drug regimens increasing over time. Thus,
assessment of medication appropriateness has become increas-
ingly important because of the increasing risk of adverse events
associated with polypharmacy and inappropriate prescribing.
For example, as many as 40% of prescriptions for oral
anticoagulants in nursing home participants were reported as
suboptimal or inappropriate [19–20] This raises questions about
medication appropriateness among this population. These
common problems are seldom addressed even though clinical
practice guidelines emphasize appropriate prescription for
standardizing management and managing medical problems.[21]
Since older people with chronic diseases are vulnerable, treatment
goals should not only focus on lowering risks, but also try to
improve physical and mental health.[12] Hence, the present study
aimed to evaluate medication appropriateness and frailty status
among elderly aged care home residents inMalaysia with chronic
disease.2. Methods
2.1. Study design and participants
This cross-sectional study assessed medication appropriateness
and frailty status among older residents (≥65 years) of aged care
homes associated with at least one chronic medical condition. The
sample size of participants aged 65 and abovewas estimated based
on the prevalence of population aged 65 years and above in
Malaysia (5.9%, 2015),[22] with 95% conﬁdence level and 5% of
margin of error. A total of 17 private aged care homes around
Klang Valley in Malaysia were approached to recruit 202
participants, who met inclusion criteria. The criteria included
being at least 65 years old, staying in the facilities for >3 months,
with one chronicmedical condition and receiving at least one long-
termmedication, provided consent to participate in this study and
able to articulate. Individuals who were critically ill, bedridden, or
had clinically diagnosed cognitive impairment were excluded. An
interviewer–administered data collection form was used.
The validated English version of the data form was translated
into Malay and Chinese using a forward–backward translation
process, with the aim of obtaining versions conceptually
equivalent to the English version. The forward translators were
health professionals who were native speakers of the relevant
language, proﬁcient in English and with appropriate knowledge
of the health concepts used in the study. Without prior exposure
to the form, the Malay and Chinese versions of the form were
translated back to English by 2 independent translators.
2.2. Measurement of frailty
Frailty was measured using Groningen Frailty Indicator (GFI),
which was developed by Steverink et al, and has been validated in
institutionalized elderly.[23] GFI that contains 15 dichotomous
items can range from a total score of 0 (normal activity without
restriction) to 15 (completely disabled). Participants with a GFI
score of 4 and above were considered frail.
2.3. Assessment of medication appropriateness
The medication appropriateness of participants was assessed
using Medication Appropriateness Index (MAI), Beers’ criteria
(2015), and START/STOPP criteria (2014).[24–26] Beers criteria
and START/STOPP criteria were applied to identify potentially
inappropriate medication (PIM) and potentially inappropriate
prescribing (PIP), respectively. On the contrary, MAI assesses the2appropriateness of a medication on 10 criteria: indication,
effectiveness, dosage, correct directions, practical directions,
drug–drug interaction, drug–disease interaction, duplication,
duration, and cost. Appropriate responses were scored 1, whereas
inappropriate, do not know, and not applicable responses were
scored 0.[24] The 10 criteria were then combined with the weights
of 3 for indication and effectiveness; 2 for dosage, correct
directions, drug–drug interaction, and drug–disease interaction;
and 1 for practical directions, duplication, duration, and cost. For
each medication, the weighted sum across the 10 criteria was
calculated, with anMAI range of 0 (fully appropriate) to 18 (fully
inappropriate) for each medication. The average MAI per
medication for each participant was then calculated. A higher
score indicates less appropriate prescribing.2.4. Number of medications and chronic diseases
The clinical parameters including list of current medical
conditions and medications were gathered. The data were
obtained from participants’ medical records. For this study,
polypharmacy was deﬁned as individuals who are dispensed with
5 or more concurrent medicines at one time during the study
period. The frequency of chronic diseases experienced by
participants was also recorded.
2.5. Data collection and analysis
Before baseline interview, consent was obtained after explaining
research goals to the participants who corresponded to the
inclusion and exclusion criteria. Each interview was conducted in
the participant’s preferred language (English,Malay, or Chinese).
Sociodemographic information included age, ethnicity, educa-
tion, occupation, alcohol consumption, and cigarette smoking
(nonsmokers, past smokers, and current smokers). These were
collected from participants. Statistical analysis was performed
using SPSS version 23 and STATA IC version 12 with statistical
signiﬁcance set at a P value of .05. The results are presented as
percentages or means and standard deviations. The differences
between the variables were examined using independent t test
(e.g., occurrence of polypharmacy and medication appropriate-
ness parameters). Pearson’s correlation test was used to assess the
correlation between the variables (e.g., between GFI score and
medication appropriateness parameters).
The International Medical University Joint-Committee on
Research and Ethics (Project ID: BPI-1-13-(52)) gave ethical
approval for the study. Participants’ personal data were stored in
a password-protected ﬁle accessible only to the researchers. No
personal data was disclosed, and the study results are reported as
deidentiﬁed data.
3. Results
3.1. Sociodemographic characteristics of participants
A total of 202 participants from 17 aged care homes participated
in this study. Of these participants, 126 (62%) were female. Most
of the study participants (n=164, 81%) were taking medications
for CVD; 42% (n=85) were taking medications for central
nervous system (CNS)-related diseases and 34% (n=69) for DM.
Table 1 shows sociodemographic characteristics of the partic-
ipants, stratiﬁed by types of medications. The mean age of all
participants was 76.8±7.8 years old. Although most of the
participants taking medications for CVD and CNS diseases were
between the age of 75 and 84 years old, participants taking
Table 1
Sociodemographic characteristics of study residents.
Variables
Residents taking
CVD medication (n=164)
Residents taking medications
for DM (n=69)
Residents taking CNS
medication (n=85)
n % n % n %
Gender Male 66 40.2 20 29.0 26 30.6
Female 98 59.8 49 71.0 59 69.4
Age (mean±SD) 76.8±7.6 75.2±7.0 76.9±7.9
Age group 65–74 63 38.4 31 44.9 30 35.3
75–84 73 44.5 28 40.6 40 47.1
>85 28 17.1 10 14.5 15 17.6
Ethnicity Chinese 154 94.2 62 89.9 78 91.8
Indian 10 5.8 7 10.1 6 7.1
Malay 0 0 0 0 1 1.2
Marital status Married 89 54.3 41 59.4 48 56.5
Single 51 31.1 16 23.2 22 25.9
Widowed 19 11.6 10 14.5 9 10.6
Divorced 5 3.0 2 2.9 6 7.1
Education level None 44 26.8 17 24.6 21 24.7
Primary 56 34.1 28 40.6 28 32.9
Secondary 48 29.3 19 27.5 26 30.6
Tertiary 16 9.8 5 7.2 10 11.8
Previous occupation Physical 36 22.0 17 24.6 33 38.8
Nonphysical 128 78.0 52 75.4 52 61.2
No. of children 2.3±2.3 2.6±2.3 2.4±2.4
No. of siblings 3.8±3.3 4.3±3.2 3.6±3.4
Frailty status Frail 126 76.8 52 75.4 69 81.2
Nonfrail 38 23.2 17 24.6 16 18.8
CNS= central nervous system, CVD= cardiovascular disease, DM=diabetes mellitus.
Hasan et al. Medicine (2017) 96:35 www.md-journal.comhypoglycaemic medications were mostly between the ages of 65
to 74 years old. Almost all the participants were of Chinese
ethnicity (n=189, 93%). More than half of the participants were
married (n=106, 52%). Nearly one-quarter of participants did
not receive any formal education (n=54, 27%).3.2. Utilization of medications for chronic conditions
Pattern of CVD medication utilization is shown in Figure 1.
Antihyperlipidemic agents (n=93, 46%) were most frequently
prescribed to the participants, with most being statins. This was
followed by CCBs (n=86, 42%). There were 80 (39%)
participants taking angiotensin inhibitors, with participants
taking ARBs (n=27, 13%) about half of those taking ACE
inhibitors (n=53, 26%). Participants taking antiplatelet dose
aspirin (n=42, 21%) almost doubled those taking other0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0%
Anlipidemic agents
CCBs
Angiotensin inhibitors
Aspirin
Beta-blockers
Diurecs
Anplatelets
Ananginal agents
Ancoagulants
Anarrhythmic agents 
Alpha-blockers
Figure 1. Percentage use of medications for CVS-related disorders.
3antiplatelet agents (n=23, 11%). Of the participants taking
diuretics (n=33, 16%), most were on thiazides (n=21, 10%).
Hypoglycaemic agent use is shown in Figure 2. Participants
prescribed with biguanides (n=56, 28%) were double of those
prescribed with sulfonylureas (n=28, 14%). Similar number of
participants (n=7, 3.4%) were prescribed with DPP-4 inhibitors
and insulin. Participants prescribed with short-acting insulin (n=
5, 3%) also concurrently prescribed with intermediate-acting
insulin.
Pattern of CNS medications utilization is shown in Figure 3.
CNS medications used most frequently were ﬁrst-generation
antihistamines (n=29, 14%). This was followed by antipsy-
chotics (n=19, 9%) and anti-Parkinson agents (n=18, 9%).
Among participants who received antipsychotics, second-gener-
ation agents were being favored over the ﬁrst-generation agents
(n=12, 5.9% vs n=7, 3.4%). In addition, SSRI was the most0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0%
Biguanides
Sulfonylureas
DPP-4 inhibitors
Insulin
Others
Figure 2. Percentage use of medications for diabetes.
0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0%
First-generaon anhistamines
Anpsychocs
An-parkinson agents
Andepressants
Benzodiazepines
Opioids
Anconvulsants
An-demena agents
Others
Figure 3. Percentage use of medications for CNS-related disorders.
Table 2
Descriptive data of medication appropriateness parameters, GFI,
and chronic diseases (n=202).
Variables Mean SD
No. of medication per resident 4.9 2.6
Occurrence of polypharmacy (n, %) 98 (48.3)
No. of CVD medication per resident 2.1 1.6
No. of hypoglycaemic medication per resident 0.5 0.8
No. of CNS medication per resident 0.9 1.3
Resident with at least one PIP (n, %) 83 (40.9)
No. of PIP per resident 0.6 0.8
Resident with at least one PIM (n, %) 73 (36.0)
No. of PIM per resident 0.5 0.8
MAI per resident 0.6 0.6
Average no. of chronic disease 2.9 1.5
Average GFI score 6.4 3.6
CNS= central nervous system, CVD= cardiovascular disease, DM=diabetes mellitus; GFI=
Groningen Frailty Indicator, MAI=medication appropriateness Index, PIM=potentially inappropriate
medication, PIP=potentially inappropriate prescribing.
Hasan et al. Medicine (2017) 96:35 Medicinecommonly prescribed class of antidepressants (n=13, 6%). In
case of benzodiazepines, the intermediate-acting agents were
most commonly prescribed to the participants (n=12, 6%).
3.3. Medication appropriateness
Table 2 presents information about medication appropriateness.
On average, each participant received 2.1±1.6 of CVD, 0.5±0.8
of hypoglycaemic, and 0.9±1.3 of CNS medications, respective-
ly. Nearly half (n=98, 48%) of the study participants were
associated with polypharmacy. There were 41% of participants
found to have at least one PIP, with a mean number of 0.6±0.8
PIPs in each participant. Percentage of participants (36%)
prescribed with at least one PIM was lower than those prescribed
with at least one PIP, with a mean number of 0.5±0.8 PIPs in
each participant. On the contrary, the average MAI score of
participants was 0.6 (range: 0–6).3.4. Frailty status
More than three-quarters of participants (n=154, 76%) were
frail, with an average GFI score of 6.4±3.6. Table 3 shows the
relationship between GFI and parameters of medication
appropriateness. The number of medications used per participant
correlated signiﬁcantly and positively (r=0.21, P= .002) with
GFI score. The numbers of CVD, hypoglycaemic, and CNS
medications per participant, correlated negatively with GFI score
(r=0.02, r=0.23, r=0.30, respectively). However, these
correlations were statistically signiﬁcant only for hypoglycaemic
and CNS medications (both P=0.001). PIP and PIM per
participant correlated positively with GFI score, but were not
statistically signiﬁcant (r=0.09, P> .05).Table 3
Relationships of medication appropriateness parameters with GFI an
Variables
GFI
Correlation coefﬁcient (r
No. of medication per resident 0.21
No. of CVD medication per resident 0.02
No. of hypoglycaemic medication per resident 0.23
No. of CNS medication per resident 0.30
No. of PIP per resident 0.09
No. of PIM per resident 0.09
MAI per resident 0.11
CNS= central nervous system, CVD= cardiovascular disease, DM=diabetes mellitus; GFI=Groningen F
PIP=potentially inappropriate prescribing. Coefﬁcients and P values were obtained using Pearson corre
43.5. Comorbidity status
The mean number of chronic diseases of participants was 2.9
(SD=1.5). Table 3 shows the relationship between number of
chronic diseases and parameters of medication appropriateness.
The number of medications per participant correlated signiﬁ-
cantly and positively (r=0.65, P= .001) with GFI score. When
analyzed according to the 3 groups of medications, we found that
the number of medications (CVD, hypoglycaemic, and CNS) per
participant correlated negatively with GFI score (r=0.04, r=
0.23, r=0.25, respectively). Among the 3 groups, only the
numbers of hypoglycaemic and CNS medications per participant
achieved statistical signiﬁcance (both P= .001). Both the number
of PIP and the number of PIM per participant correlated
positively and signiﬁcantly with GFI score (r=0.20, P= .004; r=
0.14, P= .043). Although the MAI score per participant
correlated positively with number of chronic diseases, the result
was not statistically signiﬁcant (r=0.12, P= .082).3.6. Polypharmacy
The number of hypoglycaemicmedicationswas signiﬁcantly lower
among participants with polypharmacy than participants without
polypharmacy (0.4±0.7 vs 0.6±0.9; P= .047) (Table 4). The
other 2 variables (number of CVDmedications and the number of
CNS medications) did not achieve statistical signiﬁcance (both
P> .05). Although the number of PIP and the number of PIMwered number of chronic diseases.
No. of chronic disease
) P Correlation coefﬁcient P
.002 0.65 .001
.807 0.04 .554
.001 0.23 .001
.001 0.25 .001
.227 0.20 .004
.213 0.14 .043
.124 0.12 .082
railty Indicator, MAI=medication appropriateness index, PIM=potentially inappropriate medication,
lation test.
Table 4
Medication appropriateness parameters, by presence or absence
of polypharmacy.
Polypharmacy
Yes No
Variables Mean±SD Mean±SD P
No. of medication per resident 7.1±2.0 2.9±1.0 .001
No. of CVD medication per resident 2.1±1.6 2.1±1.7 .916
No. of hypoglycaemic medication
per resident
0.4±0.7 0.6±0.9 .047
No. of CNS medication per resident 0.8±1.4 0.9±1.2 .551
No. of PIPs per resident 0.7±0.9 0.4±0.6 .022
No. of PIMs per resident 0.6±0.9 0.4±0.6 .039
MAI per resident 0.6±0.5 0.6±0.7 .918
Average no. of chronic disease 3.8±1.6 2.1±1.0 .001
Average GFI score 7.2±3.4 5.7±3.6 .002
CNS=central nervous system, CVD= cardiovascular disease, DM=diabetes mellitus; GFI=Groningen
Frailty Indicator, MAI=medication appropriateness index, PIM=potentially inappropriate medication,
PIP=potentially inappropriate prescribing. P values were obtained using independent t test.
Hasan et al. Medicine (2017) 96:35 www.md-journal.comsigniﬁcantly higher in participants with polypharmacy (both
P< .05), the MAI score was almost the same between participants
with and without polypharmacy (P= .918). Both the number of
chronic diseases and the GFI score were signiﬁcantly higher in
participants with polypharmacy (both P< .05).4. Discussion
This study evaluated medication appropriateness and frailty
among residents of aged care homes in Malaysia. A signiﬁcant
proportion of study participants were on medications for CVD,
CNS-related disease, and diabetes mellitus. Polypharmacy was a
feature of themedication regimens of most of the participants and
most had at least one PIP and one PIM. The average MAI score
was 0.6 (range: 0–6). More than three-quarters of participants
were frail as measured using GFI, with an average GFI score of
6.4±3.6. The number of medications per participant correlated
signiﬁcantly and positively with GFI score.
There was a relatively high prevalence of potentially
inappropriate medication use among study participants, with
36% and 41% of participants with at least one PIM and PIP,
respectively. This prevalence was higher when compared with
another Malaysian study conducted in similar settings, which
reported a percentage of 24% to 33%.[27] This difference may be
attributable to variations of prescribing or differences in the care
provided. Nevertheless, the results were lower when compared
with the global trend, in which an overall weighted point
prevalence of 43.2% was reported in a recent systematic review
(2016) which included studies from 18 different countries.[28]
This might be because the review analyzed studies mainly from
European countries which implement the multidose dispensing
system that was associated with the use of potentially
inappropriate medications.[28–30]
The mean number of medications was 4.9±2.6, with almost
half (48%) with polypharmacy. A similar study in Malaysia
reported a slightly lower mean number of medications (4.7±2.8)
and percentage (44%) of participants experiencing polyphar-
macy.[31] The ﬁndings support the hypothesis that the problem of
polypharmacy is quite prevalent among residents of aged care
homes taking chronic medications in Malaysia.
Participants with polypharmacy in the present study had
signiﬁcantly higher numbers of PIP and PIM than their5counterparts without polypharmacy. The ﬁnding is in accordance
with other studies that report a relationship between the total
number of medications and likelihood of receiving potentially
inappropriate medications.[32–34] Similarly, the ﬁnding that study
participants with higher number of chronic diseases (multiple
comorbidities) had higher events of polypharmacy is also
consistent with a study reporting multiple comorbidities as one
factor associated with polypharmacy among aged care home
residents.[35] In this study, polypharmacy was signiﬁcantly lower
among participants on hypoglycaemic medications than those on
CVD or CNS medications. This may be ascribed to heightened
awareness of prescribers of interaction between medications that
can result in hypoglycaemia or hyperglycaemia, diminished
autonomic warning symptoms of hypoglycaemia, and alteration
of the blood glucose-lowering effect of hypoglycaemic medi-
cations.[36]
There can be signiﬁcant adverse clinical consequences of
polypharmacy in the elderly in care homes, as these individuals
constitute the frailest segment of the geriatric population. In
the present study occurrence of polypharmacy was signiﬁcant-
ly associated with higher frailty. There was signiﬁcant
correlation between number of medications per participant
and GFI score. Polypharmacy has been associated with frailty
among home-dwelling elderly in a French study.[37] This
ﬁnding is consistent with the association between polyphar-
macy, cognitive impairment and impairment of physical
fucntioning.[38,39]
About three-quarters (76%) of the study participants were
frail. This prevalence was much higher than the prevalence of
frailty (46.9%) among general aged care home participants as
reported in a recent systematic review and meta-analysis
(2015).[40] The difference in prevalence may be attributed to
differences in the criteria used to deﬁne frailty, that is, according
to the operational deﬁnition used.[41]Most of the studies included
in the systematic review and meta-analysis deﬁned frailty
according to Field Frailty Indicator and the only included study
which used GFI to deﬁne frailty reported a prevalence (62.1%)
which was closer to this study.[40] Also, we included only elderly
participants who were receiving long-term medications. This
might contribute to the observed difference in prevalence since
these participants may have multiple comorbidities and self-
perceived impairments of physical ﬁtness, which are 2 of the
frailty indicators in GFI.
The correlation between GFI score and the number of PIP and
PIM demand attention. Although there is lack of evidence that
associates the potentially inappropriate medication use as
detected using Beers criteria and other implicit measures such
as MAI with negative outcomes in clinically deﬁned frail older
adults, frail older adults are likely to be more susceptible to
medication-related adverse effects owing to attenuated physio-
logical changes observed in frailty.[42] Therefore, it is advisable to
use caution in prescribing to aged care home residents who are
more frail than their community counterparts. Nonetheless, it is
encouraging to observe signiﬁcant negative correlations between
GFI score and number of CNS medications, which suggests safer
prescribing of CNS medications to frail elderly patients. This
ﬁnding is expected since psychotropic medications are notori-
ously associated with increased risk of fall and other adverse
consequences.[43]
With regard to comorbidity status, it was not surprising to
observe a signiﬁcant correlation between number of chronic
diseases and the number of PIP and the number of PIM because
patients with multiple comorbidities are more likely to be at
Hasan et al. Medicine (2017) 96:35 Medicineincreased polypharmacy-associated risk for inappropriate pre-
scribing. It was observed that the number of chronic diseases
correlated signiﬁcantly with the number of medications per
participant. Although it would be instinctive to also expect a
positive correlation between the number of each group of
medications used and the number of chronic diseases, the
opposite was true where the number of each type of medication
used. CNS medications, correlated negatively and signiﬁcantly
with the number of chronic disease. A study reported that
patients with new episodes of depression were less likely to be
prescribed antidepressants if they had multiple comorbidities.[44]
The prescribing pattern of CNS medications merits discussion.
Many of the Beers and START/STOPP criteria involve
medications acting on the brain. We observed that more
second-generation antipsychotic agents were prescribed than
ﬁrst-generation agents. Both “generations” have comparable
clinical but second-generation agents have fewer extrapyramidal
effects.[45] A plethora of studies have reported that more second-
generation antipsychotics were prescribed to nursing home
residents than ﬁrst-generation antipsychotics.[46–48] Prescribing
ﬁrst-generation antipsychotics is considered potentially inappro-
priate in the STOPP criteria. Prescribing of both ﬁrst- and second-
generation antipsychotics is considered potentially inappropriate
in the Beers criteria.[25,26] With regard to antidepressants, SSRIs
were more commonly prescribed than tricyclic agents. Tricyclic
agents are associated with fall risk due to anticholinergic side
effects. SSRIs have fewer anticholinergic side effects and are
generally well tolerated by elderly patients.[49,50] Tricyclic
antidepressants are potentially inappropriate in both STOPP
and Beers criteria.[25,26] Although short- to intermediate-acting
benzodiazepine were more frequently used relative to long-acting
agents in the present study, it is advised that benzodiazepine
should be avoided if at all possible in elderly patients regardless of
duration of benzodiazepine action. Increased fall risk is similar
whether agents of short, intermediate, or long duration of action
are used.[51] All benzodiazepines are thus regarded as potentially
inappropriate in both the STOPP and Beers criteria.[25,26]
There are mainly 2 limitations in this study. First, the cross-
sectional design does not allow the establishment of any
cause–effect relationship. Second, the relatively small number
of participants, from aged care homes in urban central
Peninsular Malaysia, limit the generalizability. The reliability
of medication-related data was ensured by all good medication
storage and administration practice in the homes used in the
study. The results of certain laboratory tests such as serum
sodium and creatinine levels are required to assess several
criteria of STOPP. These laboratory records were not available
in the medical charts of some participants, which might lead to
underreporting of PIP.
In summary, this study identiﬁes a high prevalence of
polypharmacy and frailty among Malaysian aged care homes
participants with chronic diseases. Participants with polyphar-
macy had signiﬁcantly higher numbers of both PIP and PIM than
their counterparts without polypharmacy. Polypharmacy and
long standing frailty could contribute to declining health, and
vice versa. The ﬁndings reinforce the need for periodic medication
review.Acknowledgments
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